Mesoblast Limited Reports Changes in Equity Securities and Director Interests

On July 14, 2026, Mesoblast Limited filed a Form 6-K with the SEC detailing several updates regarding its equity securities and director interests. The filing includes notifications of the issuance, conversion, and cessation of various unquoted equity securities, as well as an application for the quotation of securities on the Australian Securities Exchange (ASX). Notably, the report includes a 'Change of Director’s Interest Notice' (Appendix 3Y) for CEO and Executive Director Dr. Silviu Itescu. According to the notice, 278,571 options held by Dr. Itescu lapsed on July 7, 2026, because they were tied to a duplicative milestone that had already been achieved. Following this lapse, Dr. Itescu continues to hold 78,958,928 ordinary shares (both direct and indirect) and 18,196,587 options. No new securities were acquired by the director in this transaction, and the change did not involve any on-market or off-market trades during a closed period.